Apalutamide in the treatment of a patient with non-metastatic castration-resistant prostate cancer Case report
Article Sidebar
Main Article Content
Abstract
The treatment of patients with prostate cancer, who do not qualify for the radical therapy is based on the use of surgical or pharmacological castration methods. The effectiveness of the so-called androgen deprivation tends to decrease over time. Even in the absence of distant metastases on imaging studies, the resistance for the hormonal castration may be developed. At this moment, the use of new generation androgen receptor inhibitors may reduce the risk of metastases or death. The paper presents a case report of a patient with prostate cancer without distant metastases who started therapy with apalutamide at the moment of developing re-sistance to the pharmacological castration.
Downloads
Metrics
Article Details
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Stelmach A, Potemski P, Borówka A et al. Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych. Nowotwory układu moczowo-płciowego. Rak gruczołu krokowego. Via Medica, Gdańsk 2013.
3. Potocki PM, Wysocki PJ. Evolution of prostate cancer therapy. Part 1. Oncol Clin Pract. 2022; 18(3): 177-88. http://doi.org/10.5603/OCP.2021.0001.
4. Ministerstwo Zdrowia. Programy lekowe (access: 22.11.2022).
5. NCCN Guidelines Version 1.2023. Prostate cancer (access: 16.10.2022).
6. Smith MR, Saad F, Chowdhury S et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018; 378(15): 1408-18. http://doi.org/10.1056/NEJMoa1715546.
7. Fizazi K, Shore N, Tammela TL et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2019; 380(13): 1235-46. http://doi.org/10.1056/NEJMoa1815671.
8. Hussain M, Fizazi K, Saad F et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018; 378(26): 2465-74. http://doi.org/10.1056/NEJMoa1800536.
9. Small EJ, Saad F, Chowdhury S et al. Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC). JCO. 2020; 38(15 suppl): 5516. http://doi.org/10.1200/JCO.2020.38.15_suppl.5516.